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The recent article by Crossnohere et al. assessed the “appropriateness” of the EQ-5D for use as a 
measure of health status in Duchenne muscular dystrophy (DMD). This was investigated in terms of 
the instrument’s responsiveness (to differences in health status), convergent validity (correlation 
with disease-specific measures), feasibility and burden (how easy was the EQ-5D to understand and 
answer), and some minimal tests of content validity (did the participants think that the EQ-5D was 
consistent with “health status”). In their Abstract, the researchers conclude that they “found support 
for the appropriateness of EQ-5D to assess health status in Duchenne”.1  
We welcome the research by Crossnohere et al., but we would like to make explicit the caveat to 
their conclusion that the researchers conducted a very limited assessment of the content validity of 
the EQ-5D for use in measuring health status (or health-related quality of life, as used elsewhere in 
the manuscript) in DMD. While this is acknowledged in the Discussion of the manuscript, it is not 
clear in the Methods section and in the Abstract and there is the concern that this caveat may 
therefore be lost on a more casual reader.   
Content validity is regarded as the most important psychometric property of any patient reported 
outcome measure (PROM) according to the widely respected COSMIN guidelines, which should 
necessarily extend to preference-based measures used to generate utilities (as a special category of 
PROMs).2 Put simply, before a measure is used to inform QALYs in cost utility analysis, you would 
want to make sure you are measuring the right thing(s) (and in this context, when considering 
health-related quality of life, we argue that should be the domains that matter most to patients).   
A fuller assessment of content validity would involve asking participants, usually in a more in-depth 
interview setting, whether the instrument is comprehensive (i.e. nothing important is missing), each 
item is relevant (i.e. applicable to the target population and context of use), and each item is 
comprehensible (i.e. understood as the developers or researchers intended). Crossnohere et al. 
rightfully acknowledge that “it is important to understand whether this generic measure [EQ-5D] is 
comprehensive, relevant and understandable to people with rare conditions”. However, the 
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questions they used did not fully reflect this goal. First, no questions were asked about whether the 
EQ-5D was comprehensive. Second, participants were asked whether the EQ-5D was “consistent 
with health state of the person with Duchenne” (a majority agreed that it was) and “did or did not 
describe real health status” (of which 43% agreed). These questions do not ask about the relevance 
of each item, do not ask people to consider health-related quality of life, and may otherwise be 
difficult for lay people to understand (what is “health status”?). Finally, the authors do ask if the EQ-
5D was “easy to understand” (but not whether each item was understood as intended).  
Crossnohere et al. conclude their article recommending that “advocacy groups look holistically at 
addressing the barriers to access of therapies in rare diseases such as Duchenne, rather than honing 
in specifically on perceived shortcoming of the EQ-5D”. We would extend this to say that all 
stakeholders need to consider how value is determined in access decisions and that for rare 
diseases, where there is a paucity of clinical evidence and knowledge, modelling of value must 
capture elements that are most important to patients, including impacts on quality of life.3 The 
Duchenne UK Project HERCULES initiative has worked holistically over the past three years with all 
stakeholders to develop better understanding of the burden of illness with DMD, and sufficiency of 
current quality of life measures.4 This multi-faceted work has shown potential cause for concern 
over the use of the EQ-5D in DMD. A recent systematic review showed unsatisfactory 
comprehensiveness of the EQ-5D in DMD based on the available evidence, which is notably limited.5 
Moreover, qualitative work from the project demonstrated that certain domains of the EQ-5D may 
not be relevant for all people with DMD, such as the mobility domain focusing wholly on walking 
(and not using mobility aids, such as wheelchairs).6 As a consequence, a condition specific PROM and 
preference-based measure has been developed based on in-depth qualitative interviews with people 
with DMD, designed to have greater content validity: the DMD-QoL and DMD-QoL-8D.7,8 
In summary, while we welcome Crossnohere et al.’s contribution, we would like to emphasise to 
readers that no conclusions can yet be drawn that the EQ-5D is measuring what matters to people 
MEASURING WHAT MATTERS – USE OF THE EQ-5D IN DMD 
4 
with DMD and their caregivers with regards to health-related quality of life (or the “quality” in a 
quality-adjusted life year [QALY]). We argue that content validity should be a fundamental aspect in 
determining the appropriateness of any outcome measure. Therefore, we recommend that evidence 
on the content validity of the instrument is considered alongside evidence of other psychometric 
properties in order to make conclusions on the appropriateness of EQ-5D for use in DMD.  
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